FDA Approves First Generic Abilify

Share this content:
FDA Approves First Generic Abilify
FDA Approves First Generic Abilify

WEDNESDAY, April 29, 2015 (HealthDay News) -- The first generic versions of the atypical antipsychotic drug Abilify (aripiprazole) have been approved by the U.S. Food and Drug Administration to treat schizophrenia or bipolar disorder.

License to produce the drug in multiple strengths was approved for Alembic Pharmaceuticals, Hetero Labs, Teva Pharmaceuticals, and Torrent Pharmaceuticals, the agency said in a news release.

As with other atypical antipsychotic drugs, generic Abilify's label will contain the FDA's most stringent boxed warning that the medication poses an increased risk of death among older people with dementia-related psychosis. The label also warns of an increased risk of suicidal thinking and behavior among children, teens, and young adults.

The most common side effects of the drug are nausea, vomiting, constipation, headache, dizziness, akathisia, anxiety, insomnia, and restlessness.

More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

CDC: No Change in Level of Uninsured in U.S. in 2017

CDC: No Change in Level of Uninsured in ...

Five percent of children uninsured in 2017, 41.3 and 55.0 percent had public and private coverage

Age-Related Racial Disparity Examined in Childhood Suicide

Age-Related Racial Disparity Examined in Childhood Suicide

Significantly higher incidence of suicide for black children aged 5 to 12; lower rate for black teens

Moral Distress for Docs Providing Emergency-Only Hemodialysis

Moral Distress for Docs Providing Emergency-Only Hemodialysis

Docs describe burnout and emotional exhaustion; moral distress at seeing suffering and injustice

is free, fast, and customized just for you!

Already a member?

Sign In Now »